Finerenone Across the Cardiovascular–Kidney–Metabolic Continuum: From Mechanistic Rationale to Clinical Positioning—A Narrative Review

Jacek Kubica, Aldona Kubica, Jakub Ratajczak, Robert Gajda, Łukasz Szarpak, Eliano P. Navarese · 2026

Read Finerenone Across the Cardiovascular–Kidney–Metabolic Continuum: From Mechanistic Rationale to Clinical Positioning—A Narrative Review by Jacek Kubica, Aldona Kubica, Jakub Ratajczak, Robert Gajda, Łukasz Szarpak, Eliano P. Navarese (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13163276.txt.

Description

Jacek Kubica and five co-authors review the drug finerenone in a 2026 paper on heart, kidney, and metabolic health. These three areas fail together so often that doctors now treat them as one syndrome. A hormone receptor that stays overactive drives much of the harm, even when standard drugs are in place.

Finerenone blocks that receptor in a targeted way. Trial and lab data show it calms swelling and scarring in the heart and kidneys and slows bad remodeling. The review weighs where the drug fits in care for people whose heart and kidney risk stays high on standard treatment.

Catalog record

CREATORJacek Kubica, Aldona Kubica, Jakub Ratajczak, Robert Gajda, Łukasz Szarpak, Eliano P. Navarese
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE43 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC13163276

Browse the full library · About the Tower of Babel